61. Project: Hyperhomocysteinemia And Kidney Disease (NIWI) from Project Hyperhomocystei . entire NIWI site (en), Help. Project hyperhomocysteinemia and kidney disease. switch to nl. mutation. http://www.niwi.knaw.nl/en/oi/nod/onderzoek/OND1259262/toon

Login NIWI (en) Research Information NOD - Dutch Research Database ... Powered by from "Project: Hyperhomocystei..." entire NIWI site (en) Project: Hyperhomocysteinemia and kidney disease Titel Hyperhomocysteïnemie en nierziekte Abstract Objectives: Hyperhomocysteinaemia is universal in patients with chronic renal failure and may contribute to the high risk of atherothrombotic disease in these patients. We set out to investigate causes and consequences of hyperhomocysteinaemia in chronic renal failure patients. Period Related organisations Financier: Dutch Kidney Foundation Secretariat: Institute for Cardiovascular Research (VU) Related persons Project leader: Prof.dr. A.J.M. Donker Project leader: Prof.dr. C.D.A. Stehouwer Researcher: Dr. C. van Guldener Researcher: Drs. F. Stam Related research activities (higher level) Diabetes mellitus and atherosclerosis Classification : public health and health care : biochemistry : internal medicine Back NOD page Last modified: 09-01-2004 00:00

62. ROLE OF HYPERHOMOCYSTEINEMIA IN THE DEVELOPMENT OF ATHEROSCLEROSIS 153, Return to Table of Contents. ROLE OF hyperhomocysteinemia IN THE DEVELOPMENT OF ATHEROSCLEROSIS*. J Zhou, GH Werstuck, L Watson http://www.ccs.ca/society/congress2002/abstracts/abs/a153.htm

Return to Table of Contents ROLE OF HYPERHOMOCYSTEINEMIA IN THE DEVELOPMENT OF ATHEROSCLEROSIS* J Zhou, GH Werstuck, L Watson, GS Hossain, ABL de Koning, YY Shi, SK Sood, RC Austin Henderson Research Centre and Mcmaster University, Hamilton, Ontario *Supported in part by the Heart and Stroke Foundation of Ontario DNC NEXT

63. RESISTANCE ARTERY MECHANICS IN MICE WITH HYPERHOMOCYSTEINEMIA: EFFECTS OF ANGIOT 245, Return to Table of Contents. RESISTANCE ARTERY MECHANICS IN MICE WITH hyperhomocysteinemia EFFECTS OF ANGIOTENSIN II. Mario Fritsch http://www.ccs.ca/society/congress2002/abstracts/abs/a245.htm

Return to Table of Contents RESISTANCE ARTERY MECHANICS IN MICE WITH HYPERHOMOCYSTEINEMIA: EFFECTS OF ANGIOTENSIN II Mario Fritsch Neves, Agostino Virdis, Rima Rozen*, Ernesto L Schiffrin Clinical Research Institute of Montreal, University of Montreal and *Montreal Children’s Hospital Research Institute, McGill University, Montreal, Quebec, Canada Hyperhomocysteinemia (H-Hcy) may be an independent risk factor for atherosclerotic vascular disease. The purpose of this study was to evaluate whether hyperhomocysteinemia may induce direct vascular changes. Wild-type (+/+) and heterozygous (+/-) methylenetetrahydrofolate reductase (Mthfr) knockout mice, a model of mild H-Hcy, were divided in four groups for a 2-week treatment: wild-type with vehicle infusion (+/+ sham), wild-type with angiotensin (Ang) II infusion (400 ng/Kg/min s.c.), Mthfr +/- sham and Mthfr +/- with Ang II. Second-order branches of mesenteric arteries (lumen diameter < 300 mm) were mounted on a pressurized myograph and exposed to intraluminal pressures ranging from 3 to 140 mmHg. Media thickness and lumen diameter were measured at each pressure level to determine wall mechanical properties. In wild-type mice Ang II determined eutrophic remodeling, increasing media-to-lumen (M/L) ratio (7.5 ± 0.3 vs 5.7 ± 0.2 % ,p <0.01) but not media cross-section (8375 ± 703 vs 9527 ± 494, p>0.05). In Mthfr +/- mice Ang II induced hypertrophic remodeling with increased M/L ratio (7.2 ± 0.2 vs 6.3 ± 0.3 %, p

64. Blackwell Synergy - Cookie Absent CASE REPORT. Heterozygous methylene tetrahydrofolate reductase mutation with mild hyperhomocysteinemia associated with deep vein thrombosis. hyperhomocysteinemia. http://www.blackwell-synergy.com/links/doi/10.1111/j.1365-2257.2004.00585.x/full

Home An Error Occurred Setting Your User Cookie A cookie is a small amount of information that a web site copies onto your hard drive. Synergy uses cookies to improve performance by remembering that you are logged in when you go from page to page. If the cookie cannot be set correctly, then Synergy cannot determine whether you are logged in and a new session will be created for each page you visit. This slows the system down. Therefore, you must accept the Synergy cookie to use the system. What Gets Stored in a Cookie? Synergy only stores a session ID in the cookie, no other information is captured. In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a web site to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it. Please read our for more information about data collected on this site.

65. Blackwell Synergy - Cookie Absent hyperhomocysteinemia in pediatric and young adult renal transplant recipients. hyperhomocysteinemia in renal transplant recipients with cyclosporine. http://www.blackwell-synergy.com/links/doi/10.1046/j.1399-3046.2003.00144.x/enha

Home An Error Occurred Setting Your User Cookie A cookie is a small amount of information that a web site copies onto your hard drive. Synergy uses cookies to improve performance by remembering that you are logged in when you go from page to page. If the cookie cannot be set correctly, then Synergy cannot determine whether you are logged in and a new session will be created for each page you visit. This slows the system down. Therefore, you must accept the Synergy cookie to use the system. What Gets Stored in a Cookie? Synergy only stores a session ID in the cookie, no other information is captured. In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a web site to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it. Please read our for more information about data collected on this site.

66. WebMD Health Re hyperhomocysteinemia by CardiostarUSA1, on 4/30/2004 101440 PM Hi Meanwhile There are even bigger words used in the medical community. http://boards.webmd.com/message.asp?message_id=6680009

67. Nephrology Nursing Journal : Hyperhomocysteinemia In End Stage Renal Disease: Is Nephrology Nursing Journal hyperhomocysteinemia in end stage renal disease is treatment necessary? (Continuing Education). @ HighBeam Research. http://static.highbeam.com/n/nephrologynursingjournal/april012002/hyperhomocyste

eLibrary Web Tour Become a Member ... Customer Support Question / Keyword(s): Advanced Search Current Article: Hyperhomocysteinemia in end stage renal disease: is treatment necessary? (Continuing Education). Start N Nephrology Nursing Journal April 01, 2002 ... Hyperhomocysteinemia in end stage renal disease: is treatment necessary? (Continuing Education). Hyperhomocysteinemia in end stage renal disease: is treatment necessary? (Continuing Education). Nephrology Nursing Journal; April 01, 2002; Snavely, Jennifer Snavely, Jennifer Nephrology Nursing Journal April 01, 2002 folic acid, hcy levels, hyperhomocysteinemia, esrd patients, sub, renal failure, patients, bostom, homocysteine, hcy, risk factor, cvd, micro, mol/l, esrd population Hyperhomocysteinemia is an independent risk factor for (1999), hyperhomocysteinemia is observed in at least 85% of patients with end stage renal disease (ESRD) undergoing maintenance peritoneal or hemodialysis. It is well known by practitioners in nephrology that

68. Diabetes Care : Hyperhomocysteinemia In Type 2 In Type 2 Diabetes.(Brief Article Diabetes Care hyperhomocysteinemia in Type 2 in Type 2 Diabetes.(Brief Article) @ HighBeam Research. Read Diabetes Care hyperhomocysteinemia http://static.highbeam.com/d/diabetescare/december012000/hyperhomocysteinemiaint

eLibrary Web Tour Become a Member ... Customer Support Question / Keyword(s): Advanced Search Current Article: Hyperhomocysteinemia in Type 2 in Type 2 Diabetes.(Brief Article) Start D Diabetes Care December 01, 2000 ... Hyperhomocysteinemia in Type 2 in Type 2 Diabetes.(Brief Article) Hyperhomocysteinemia in Type 2 in Type 2 Diabetes.(Brief Article) Diabetes Care; December 01, 2000; BUYSSCHAERT, MARTIN DRAMAIS, ANNE-SOPHIE WALLEMACQ, PIERRE F. HERMANS, MICHEL P. BUYSSCHAERT, MARTIN DRAMAIS, ANNE-SOPHIE WALLEMACQ, PIERRE F. HERMANS, MICHEL P. Diabetes Care December 01, 2000 insulin resistance, thcy levels, type, hyperhomocysteinemia, diabetes mellitus, creatinine clearance, group, diabetes, plasma homocysteine, macroangiopathy, total homocysteine, folic acid, patients, groups, subjects Relationship to macroangiopathy, nephropathy, and insulin resistance OBJECTIVE The aim of this study was to determine the distribution of plasma total homocysteine (tHcy) concentrations in type 2 diabetic patients and to assess whether high tHcy values were related to chronic complications (particularly macroangiopathy and nephropathy) and/or the degree of insulin resistance.

69. Preventive Health Care, 2000 Update Screening And Management Of Preventive health care, 2000 update screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. http://collection.nlc-bnc.ca/100/201/300/cdn_medical_association/cmaj/vol-163/is

70. Ingenta: Article Summary -- Hyperhomocysteinemia Activates NF-kappaB And Inducib hyperhomocysteinemia activates NF B and inducible nitric oxide synthase in the kidney Kidney International April 2004, vol. 65, no. 4, pp. http://www.ingenta.com/isis/searching/ExpandTOC/ingenta?issue=pubinfobike://bsc/

71. Ingenta: Article Summary -- Moderate Hyperhomocysteinemia And Immune Activation Moderate hyperhomocysteinemia and Immune Activation Current Pharmaceutical Biotechnology February 2004, vol. 5, no. 1, pp. 107118 http://www.ingenta.com/isis/searching/ExpandTOC/ingenta?issue=pubinfobike://ben/

72. ANNA - Continuing Education Articles hyperhomocysteinemia in End Stage Renal Disease Is Treatment Necessary? Objectives 1. Explain homocystein metabolism and list causes of hyperhomocysteinemia. http://www.hdcn.com/anna_ce/292/292.htm

ANNA Home Page ANNA CE Link HDCN Home Page HDCN Registration Link If you dont have an Acrobat Reader installed on your computer, you may download it for free from the link below: Hyperhomocysteinemia in End Stage Renal Disease: Is Treatment Necessary? (Vol 29/No. 2. On-line test expires: 04/20/2004) To receive continuing education credit, you must read the information in this article and take an on-line post test and fill out an on-line program evaluation form. The certificate will then be generated for you as a .pdf file which you can print out locally on your computer. CE Certification by ANNA requires a handling charge that must be paid by credit card. Pricing information is available by clicking on the "Post-Test Evaluation" link below. DOWNLOAD TEST ARTICLE Please download and print the PDF file below: AUTHOR Jennifer Snavely, MSN, CRNP/BS, CNN

73. Seminar Details Professor of Biological Chemistry and Research Professor, Life Sciences Institute, University of Michigan Riboflavin and hyperhomocysteinemia Monday, May 17 http://www.genomics.upenn.edu/events/seminars/files/511.html

Pharmacology/CET Seminar Series Rowena Matthews, Ph.D. G. Robert Greenberg Professor of Biological Chemistry and Research Professor, Life Sciences Institute, University of Michigan Riboflavin and hyperhomocysteinemia Monday, May 17, 2004 12:00 PM (Refreshments Served) For more information, please contact Lise Miller at 215-898-1184

74. News - An Anti-Atherosclerosis Aid For Adults With Hyperhomocysteinemia? my personal edition vascular disorders news EMail this DGReview to a colleague DGReview An Anti-Atherosclerosis Aid For Adults With hyperhomocysteinemia? http://www.docguide.com/news/content.nsf/news/8525697700573E1885256BBB0055AE4D

Unregistered User Click here if this is not your Personal Edition Contact Us Free E-Mail Updates Journals ... Register a colleague Select a Channel Acne Addictions AIDS and HIV Allergy Other Alzheimer's Anaemia Anaesthesiology Other Angina Pectoris/MI Anxiety Arthritis Other Asthma Back Pain Bacterial Infections Bladder Cancer Bone Marrow and PBSC Transplantation Breast Cancer Burns Cardiology Other Cataract Cervical Cancer Cholesterol/Lipid Disorders Cirrhosis Clinical Pharmacology Colorectal Cancer Congestive Heart Failure Contraception Cornea COPD Cystic Fibrosis Dental and Oral Disorders Depression Dermatitis Dermatology Other Diabetes Diagnostic Radiology Dialysis Eating Disorders Elbow Emergency Medicine Endocrinology Other Epilepsy Erectile Dysfunction Fibromyalgia Gastro Other Genetics Genitourinary Other Geriatrics GERD/Gastritis GIST Glaucoma H. Pylori/Ulcer Haematology Other Hair Loss Head and Neck Cancer Hepa/Biliary Other Hepatitis C Hepatitis Other Herpes Hip HRT Hypertension IBD Immunology Infectious Other Infertility Intensive Care Interventional Cardiology Interventional Radiology Irritable Bowel Syndrome Knee Leukemias Liver Cancer Lung Cancer Lupus Lymphomas Melanoma Menopause Migraine Multiple Sclerosis Mycoses Nephrology Other Neurologic Other Nuclear Medicine Nutritional / Metabolic Other Ob/Gyn Other Obesity Oncology Other Ophth. Other

75. Entrez PubMed Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid http://arthritis-research.com/pubmed/9517760

Entrez PubMed Nucleotide Protein ... Books Search PubMed Protein Nucleotide Structure Genome Books CancerChromosomes 3D Domains Domains Gene GEO GEO DataSets HomoloGene Journals MeSH NCBI Web Site OMIM PMC PopSet SNP Taxonomy UniGene UniSTS for Limits Preview/Index History Clipboard ... Text Version Entrez PubMed Overview FAQ Tutorial New/Noteworthy ... E-Utilities PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher ... Cubby Related Resources Order Documents NLM Gateway TOXNET Consumer Health ... PubMed Central Summary Brief Abstract Citation ASN.1 MEDLINE XML UI List LinkOut Related Articles Cited in Books CancerChrom Links Domain Links 3D Domain Links GEO DataSet Links Gene Links Genome Links GEO Links HomoloGene Links Nucleotide Links OMIM Links PMC Links Cited in PMC PopSet Links Protein Links SNP Links Structure Links UniSTS Links Show: Sort Author Journal Pub Date Text File Clipboard E-mail Order J Rheumatol. 1998 Mar;25(3):441-6. Related Articles, Links Comment in: J Rheumatol. 1998 Dec;25(12):2473. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. Morgan SL, Baggott JE, Lee JY, Alarcon GS.

76. PCCU Volume 17, Lesson 3 hyperhomocysteinemia. The stenosis. hyperhomocysteinemia has also been shown to be a risk factor for venous thromboembolic disease. http://www.chestnet.org/education/online/pccu/vol17/lessons3_4/lesson03/p10.php

www ChestNet Foundation Journal home education online pccu Quick Navigation Home Education Meeting NetWorks About CME Information Editorial Board Volume 18 Volume 17 ... Volume 12 Thrombophilia: How To Test? How To Manage? By Julie Hambleton, MD Print This TOC Previous Next Hyperhomocysteinemia The early descriptions of patients with hyperhomocysteinemia involved homozygous mutations in genes encoding for enzymes of homocysteine metabolism resulting in a severe multisystem disease with neurologic and vascular manifestations. Severe elevations in plasma homocysteine are also associated with homozygous defects of the methylenetetrahydrofolate reductase ( MTHFR ) gene or of various enzymes that participate in the vitamin B cycle. However, these mutations are uncommon. The more common causes of hyperhomocysteinemia are subtle in presentation and may be caused by less severe defects in genes encoding for enzymes or from inadequate status of those vitamins that are involved in homocysteine metabolism. Inadequate folate, vitamin B , or pyridoxine may result in a substantial increase in plasma homocysteine concentrations. More recently, a thermolabile polymorphism of the

77. Www.hon.ch/cgi-bin/HONselect?browse+C18.452.648.066.480 hyperhomocysteinemiahyperhomocysteinemia. Slide 31 of 33. http://www.hon.ch/cgi-bin/HONselect?browse C18.452.648.066.480

78. HUM-MOLGEN Events: 3rd Conference On Hyperhomocysteinemia, Saarbruecken/Germany 3rd Conference on hyperhomocysteinemia, Saarbruecken/Germany, August 21, 2002, Medical Research (others). Central Laboratory Saarland http://www.hum-molgen.de/meetings/meetings/1875.html

home genetic news bioinformatics biotechnology ... 3rd Conference on Hyperhomocysteinemia, Saarbruecken/Germany August 21, 2002 Medical Research (others) Central Laboratory - Saarland Medical School , Saarbruecken/Germany 11th and 12th April 2003 Friday, 11.04.2003 Session 1: Introduction, Epidemiology and Clinical Studies Session 3: Associations of Hyperhomocysteinemia with Age and Neurodegenerative Diseases Session 4: The Role of Oxidative Stress in Hyperhomocysteinemia Saturday, 12.04.2003 Session 5: Hyperhomocysteinemia in Women and Impaired Pregnancy Session 6: Diet and Genetics in Hyperhomocysteinemia Session 7: Associations of Thrombosis and Renal Disease with Hyperhomocysteinemia Session 8: New Markers Organized by: Prof. Dr. W. Herrmann Invited Speakers: see Programm Deadline for Abstracts: 29th November 2002 for poster abstracts Registration: Registration fee is 150 Euro (capacity limited to 200 participants) Registration deadline is 31st January 2003 Registration online and information at http://www.uniklinik-saarland.de/zentrallabor/homocysteine-conference.html Poster abstracts may be submitted. The Organizing Committee will select which posters will be displayed after reviewing the abstract.

79. HNRCA : Hyperhomocysteinemia Associated With Poor Recall In An Nationally Repres Citation, Morris MS, Jacques PF, Rosenberg IH, Selhub J. hyperhomocysteinemia associated with poor recall in the third National Health and Nutrition Examination http://hnrcwww.hnrc.tufts.edu/publications/detail.php?id=115256

80. HYPERHOMOCYSTEINEMIA IS A RISK FACTOR FOR STROKE: REPORT OF 20 CASES hyperhomocysteinemia IS A RISK FACTOR FOR STROKE REPORT OF 20 CASES. MR Carriero, L. Chiapparini, E. Ciusani, A. Attanasio, C. Ariano http://www.kenes.com/stroke5/Abstracts/34.htm

HYPERHOMOCYSTEINEMIA IS A RISK FACTOR FOR STROKE: REPORT OF 20 CASES M.R Carriero, L. Chiapparini, E. Ciusani, A. Attanasio, C. Ariano, G.B Boncoraglio, G. Bussone, E.A Parati Istituto Nazionale Neurologico Carlo Besta, Milano, Italy Purpose: To describe cerebrovascular events in 20 patients affected by hyperhomocysteinemia. Methods: We evaluated clinical and neuroradiological findings (CT, MR, duplex US or DSA) in 20 patients (7 females, 13 males, 27 to 55 yrs). In all patients biochemical tests, serum folate, cobalamin level, homocysteine level (MEIA), protein C, protein S, antiphospholipid antibodies, FV-Leiden and protrombin mutation (20120A) were performed. Results: Conclusions: Mild hyperhomocysteinemia may be an additional thrombogenic risk factor for stroke. The inclusion of homocysteine determination is useful in stroke patients, besides high levels may be corrected with vitamins therapy.`

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 4     61-80 of 82    Back | 1  | 2  | 3  | 4  | 5  | Next 20